PSA, short for prostate-specific antigen, is the most common indicator of prostate cancer screening.
Prostate cancer accounts for 10%-20% of all types of tumors in male patients and is the most common tumor in men with slow progression; however, in men >65 years of age, the incidence increases dramatically and is the most predominant tumor threatening the lives of male patients >50 years of age. The latest epidemiological surveys show that the incidence of prostate cancer in China is increasing, accounting for the second highest male mortality rate in the West.PSA is a serum prostate-specific antigen and is currently the most common screening test for prostate cancer, with a normal reference value of less than 4ng/ml in men.
PSA can be found in normal, benign or malignant prostate tissue, in metastatic prostate cancer, in prostate fluid and in semen. In the United States, the FDA has approved prostate-specific antigen (PSA) testing as an indicator for screening men >50 years of age, and with PSA >4ng/ml, it is recommended that PSA testing in combination with prostate fingering (looking for hard nodes in the prostate) may improve the detection of prostate cancer; in early prostate cancer, the clinical value of PSA testing is greater than rectal fingering.